ArticleThe American journal of case reports2025
Adverse Dermatological Reaction to Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Mycophenolate mofetil (MMF) is a disease-modifying antirheumatic drug (DMARD) that has been reported to cause skin rashes. Systemic lupus erythematosus (SLE) is also associated with typical discoid skin lesions. This report describes the case of a 50-year-old woman with a 6-year history of SLE presenting with a 6-day history of fever and skin rash after starting treatment with MMF. CASE REPORT The patient was admitted to the hospital due to fever. Due to intolerance to cyclosporine treatment and non-compliance with treatment for half a year, the doctor determined that her SLE was active and prescribed MMF. After receiving MMF treatment, she suddenly developed drug-induced dermatitis, characterized by fever, nausea, vomiting, and diffuse erythematous rash. After stopping MMF and treating with corticosteroids and antihistamines for 8 days, her symptoms rapidly resolved. When MMF treatment was restarted, the same symptoms and rash reappeared. The fever and vomiting disappeared 1 day after drug withdrawal, confirming the association between the drug and adverse reactions. No recurrence of the rashes was observed at 2-month follow-up. CONCLUSIONS This report highlights an uncommon adverse effect of MMF and describes the onset and characteristics of the associated drug-induced dermatosis. Early identification and discontinuation of MMF are crucial for managing these adverse events and preventing long-term complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.